Cyanocobalamin as Photosensitizing Agent
Sponsor
EL Romany Ophthalmics Factory (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05395650
Collaborator
(none)
1
15
Study Details
Study Description
Brief Summary
is cyanocobalamin active as Photosensitizing Agent instead of riboflavin ? using cyanocobalamin with mix of external collagen to make crosslinking with cornea collagen to make rigid of cornea
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
1 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Cyanocobalamin as Photosensitizing Agent Using to Make Cross-linking to Cornea Collagen in Treatment of Progressive Keratoconus
Anticipated Study Start Date
:
Sep 1, 2022
Anticipated Primary Completion Date
:
Sep 1, 2023
Anticipated Study Completion Date
:
Dec 1, 2023
Outcome Measures
Primary Outcome Measures
- PRESERVATION of presence of red flare by using slit lamb [Base line]
Cyanocobalamin react with cornea collagen and format red flare
Eligibility Criteria
Criteria
Ages Eligible for Study:
20 Years
to 40 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
-
- Is 20 years or older Has been diagnosed with Keratoconus; Has no other active ocular disease; Is not pregnant or nursing;
Exclusion Criteria:
- Is under the age of 20 Has best corrected visual acuity outside 20/400; Pregnant or nursing at the time of enrollment in the study;
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- EL Romany Ophthalmics Factory
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Mina ibrahim shalalpy,
R&D Manger,
EL Romany Ophthalmics Factory
ClinicalTrials.gov Identifier:
NCT05395650
Other Study ID Numbers:
- CYHEMG
First Posted:
May 27, 2022
Last Update Posted:
May 27, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms: